News Image

Why NYSE:BMY is a Top Pick for Dividend Investors.

By Mill Chart

Last update: Mar 12, 2024

Take a closer look at BRISTOL-MYERS SQUIBB CO (NYSE:BMY), a stock of interest to dividend investors uncovered by our stock screener. NYSE:BMY excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.

Understanding NYSE:BMY's Dividend

ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:BMY scores a 7 out of 10:

  • BMY has a Yearly Dividend Yield of 4.50%, which is a nice return.
  • Compared to an average industry Dividend Yield of 4.15, BMY pays a better dividend. On top of this BMY pays more dividend than 97.51% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.40, BMY pays a better dividend.
  • The dividend of BMY is nicely growing with an annual growth rate of 7.57%!
  • BMY has paid a dividend for at least 10 years, which is a reliable track record.

Health Analysis for NYSE:BMY

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NYSE:BMY has earned a 5 out of 10:

  • The Altman-Z score of BMY (2.40) is better than 70.65% of its industry peers.
  • BMY has a debt to FCF ratio of 3.14. This is a good value and a sign of high solvency as BMY would need 3.14 years to pay back of all of its debts.
  • BMY has a Debt to FCF ratio of 3.14. This is amongst the best in the industry. BMY outperforms 89.55% of its industry peers.

Understanding NYSE:BMY's Profitability

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:BMY scores a 7 out of 10:

  • Looking at the Return On Assets, with a value of 8.43%, BMY belongs to the top of the industry, outperforming 92.04% of the companies in the same industry.
  • BMY has a Return On Equity of 27.27%. This is amongst the best in the industry. BMY outperforms 94.03% of its industry peers.
  • The Return On Invested Capital of BMY (13.17%) is better than 91.54% of its industry peers.
  • The last Return On Invested Capital (13.17%) for BMY is above the 3 year average (12.66%), which is a sign of increasing profitability.
  • BMY has a better Profit Margin (17.83%) than 92.54% of its industry peers.
  • Looking at the Operating Margin, with a value of 24.11%, BMY belongs to the top of the industry, outperforming 92.04% of the companies in the same industry.
  • BMY has a Gross Margin of 76.44%. This is amongst the best in the industry. BMY outperforms 82.09% of its industry peers.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

For an up to date full fundamental analysis you can check the fundamental report of BMY

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (4/25/2024, 10:43:10 AM)

44.9595

-3.9 (-7.98%)

BMY News

News Image29 minutes ago - The Motley FoolBristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript

BMY earnings call for the period ending March 31, 2024.

News Imagean hour ago - The Motley FoolIs Bristol Myers Squibb Stock a Millionaire Maker?

Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.

News Imagean hour ago - ChartmillGapping S&P500 stocks in Thursday's session

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Thursday. Stay informed about the latest market trends.

News Image3 hours ago - Investor's Business DailyWhy Big Pharma Is Following Novartis' Lead In A $25 Billion Market

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

News Image4 hours ago - Investor's Business DailyAstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

News Image5 hours ago - Bristol Myers SquibbBristol Myers Squibb Reports First Quarter Financial Results for 2024
News Imagea day ago - Market News VideoSee Which Of The Latest 13F Filers Holds Bristol Myers Squibb
News Image3 days ago - InvestorPlace5 Crash-Proof Stocks to Buy Immediately

We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks.

News Image3 days ago - Bristol Myers SquibbBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
News Image5 days ago - Yahoo Finance3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations

These stocks pay between 3.2% and 6.7% in dividends.

News Image5 days ago - The Motley Fool3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations

These stocks pay between 3.2% and 6.7% in dividends.

News Image6 days ago - InvestorPlaceThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?

Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.

BMY Links
Follow us for more